Dialysis Safety Outlook: 15G-18G Safety AVF Needles for Chronic Kidney Disease Treatment
公開 2026/04/03 16:18
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Safety Arteriovenous Fistula (AVF) Needle - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Safety Arteriovenous Fistula (AVF) Needle market, including market size, share, demand, industry development status, and forecasts for the next few years.
For hemodialysis nurses, dialysis center managers, and healthcare providers, preventing needlestick injuries during vascular access procedures is critical for healthcare worker safety and infection control. The global Safety Arteriovenous Fistula (AVF) Needle market addresses this need through medical consumables used for hemodialysis, allowing blood withdrawal and return through the arteriovenous fistula. These needles feature needlestick injury prevention design and safety lock mechanisms to reduce accidental injuries to healthcare workers, enhance puncture safety, and improve patient comfort. They are commonly used in regular hemodialysis treatments for patients with chronic kidney disease.
The global market for Safety Arteriovenous Fistula (AVF) Needle was estimated to be worth US$ 142 million in 2025 and is projected to reach US$ 187 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, global sales reached 229 million units, with an average price of 0.6 USD per unit. This growth reflects increasing adoption of safety-engineered devices in dialysis settings.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097205/safety-arteriovenous-fistula--avf--needle
Needlestick Prevention for Hemodialysis Vascular Access
The Safety Arteriovenous Fistula (AVF) Needle is a medical consumable used for hemodialysis, allowing blood withdrawal and return through the arteriovenous fistula (AVF). It features a needlestick injury prevention design and a safety lock mechanism to reduce accidental injuries to healthcare workers, enhance puncture safety, and improve patient comfort, and is commonly used in regular hemodialysis treatments for patients with chronic kidney disease.
Safety mechanisms include passive or active needle shielding after use, retractable needle designs, and audible/tactile lock confirmation. Needle gauges range from 15G to 18G (larger diameter for high blood flow rates). Winged design for secure fixation and reduced vessel trauma.
Industry Segmentation: Needle Gauges & End-Users
The Safety AVF Needle market is segmented by needle diameter and healthcare setting:
15G: Largest diameter for high-flow hemodialysis (400-500 mL/min). A dialysis center reported that 15G needles are preferred for patients with well-developed fistulas.
16G: Standard gauge for most hemodialysis patients (300-400 mL/min flow rate). Most commonly used gauge.
17G: Smaller diameter for new fistulas or patients with smaller vessels.
18G: Smallest gauge for pediatric patients or fragile vessels.
Others: Specialized gauges for specific patient populations.
Application Segments
Hospital: Dialysis units within hospitals for inpatient and outpatient hemodialysis.
Clinic: Freestanding dialysis clinics. A large dialysis provider reported that safety AVF needles reduced needlestick injuries by 60% after conversion from standard needles.
Dialysis Center: Specialized hemodialysis facilities.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Passive safety mechanisms (auto-activation after withdrawal) reduce reliance on user activation. Ultra-thin wall needle technology for improved flow rates with smaller gauge sizes. Low-friction coatings for smoother insertion and reduced patient discomfort.
The trend toward needlestick prevention regulations (OSHA, EU directives) drives conversion from standard to safety AVF needles. Increased hemodialysis patient population (chronic kidney disease, diabetes prevalence) expands market. Reimbursement policies for safety devices in various countries support adoption.
Regional Market Dynamics
Asia-Pacific dominates the safety AVF needle market, driven by large hemodialysis patient populations in China, Japan, India, and Southeast Asia, and cost-sensitive procurement. China leads in production and consumption.
North America follows, with strong safety device regulations (OSHA Needlestick Safety and Prevention Act) and high adoption rates. Europe has steady demand with EU needlestick regulation compliance.
Competitive Landscape
Key players include B. Braun, Fresenius, Nipro, JMS, Kawasumi Lab, NxStage Medical, Asahi Kasei, Beldico, Farmasol, Hemoclean, Bain Medical, Tiankang Medical, Hongda Medical, Baihe Medical, Dalian Aohua Medical Polymer Equipment, Sansin Medical, Zhejiang Kindly Medical Devices, and Ningbo Tianyi Medical Appliance.
Market Segmentation
The Safety Arteriovenous Fistula (AVF) Needle market is segmented as below:
By Company
B. Braun
Fresenius
Nipro
JMS
Kawasumi Lab
NxStage Medical
Asahi Kasei
Beldico
Farmasol
Hemoclean
Bain Medical
Tiankang Medical
Hongda Medical
Baihe Medical
Dalian Aohua Medical Polymer Equipment
Sansin Medical
Zhejiang Kindly Medical Devices
Ningbo Tianyi Medical Appliance
Segment by Gauge
15G
16G
17G
18G
Others
Segment by Setting
Hospital
Clinic
Dialysis Center
Exclusive Industry Outlook
Looking ahead, the convergence of safety AVF needle technology with needlestick prevention regulations, chronic kidney disease prevalence, and healthcare worker safety initiatives represents a steady growth opportunity. Development of needles with integrated blood detection for proper vessel placement. Radio-frequency identification (RFID) tracking for inventory management and adverse event reporting. Additionally, the expansion of home hemodialysis will drive demand for user-friendly safety devices. The ability to offer safety arteriovenous fistula needles that combine needlestick prevention, reliable flow rates, and patient comfort—supported by regulatory compliance and clinical training—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For hemodialysis nurses, dialysis center managers, and healthcare providers, preventing needlestick injuries during vascular access procedures is critical for healthcare worker safety and infection control. The global Safety Arteriovenous Fistula (AVF) Needle market addresses this need through medical consumables used for hemodialysis, allowing blood withdrawal and return through the arteriovenous fistula. These needles feature needlestick injury prevention design and safety lock mechanisms to reduce accidental injuries to healthcare workers, enhance puncture safety, and improve patient comfort. They are commonly used in regular hemodialysis treatments for patients with chronic kidney disease.
The global market for Safety Arteriovenous Fistula (AVF) Needle was estimated to be worth US$ 142 million in 2025 and is projected to reach US$ 187 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, global sales reached 229 million units, with an average price of 0.6 USD per unit. This growth reflects increasing adoption of safety-engineered devices in dialysis settings.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097205/safety-arteriovenous-fistula--avf--needle
Needlestick Prevention for Hemodialysis Vascular Access
The Safety Arteriovenous Fistula (AVF) Needle is a medical consumable used for hemodialysis, allowing blood withdrawal and return through the arteriovenous fistula (AVF). It features a needlestick injury prevention design and a safety lock mechanism to reduce accidental injuries to healthcare workers, enhance puncture safety, and improve patient comfort, and is commonly used in regular hemodialysis treatments for patients with chronic kidney disease.
Safety mechanisms include passive or active needle shielding after use, retractable needle designs, and audible/tactile lock confirmation. Needle gauges range from 15G to 18G (larger diameter for high blood flow rates). Winged design for secure fixation and reduced vessel trauma.
Industry Segmentation: Needle Gauges & End-Users
The Safety AVF Needle market is segmented by needle diameter and healthcare setting:
15G: Largest diameter for high-flow hemodialysis (400-500 mL/min). A dialysis center reported that 15G needles are preferred for patients with well-developed fistulas.
16G: Standard gauge for most hemodialysis patients (300-400 mL/min flow rate). Most commonly used gauge.
17G: Smaller diameter for new fistulas or patients with smaller vessels.
18G: Smallest gauge for pediatric patients or fragile vessels.
Others: Specialized gauges for specific patient populations.
Application Segments
Hospital: Dialysis units within hospitals for inpatient and outpatient hemodialysis.
Clinic: Freestanding dialysis clinics. A large dialysis provider reported that safety AVF needles reduced needlestick injuries by 60% after conversion from standard needles.
Dialysis Center: Specialized hemodialysis facilities.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Passive safety mechanisms (auto-activation after withdrawal) reduce reliance on user activation. Ultra-thin wall needle technology for improved flow rates with smaller gauge sizes. Low-friction coatings for smoother insertion and reduced patient discomfort.
The trend toward needlestick prevention regulations (OSHA, EU directives) drives conversion from standard to safety AVF needles. Increased hemodialysis patient population (chronic kidney disease, diabetes prevalence) expands market. Reimbursement policies for safety devices in various countries support adoption.
Regional Market Dynamics
Asia-Pacific dominates the safety AVF needle market, driven by large hemodialysis patient populations in China, Japan, India, and Southeast Asia, and cost-sensitive procurement. China leads in production and consumption.
North America follows, with strong safety device regulations (OSHA Needlestick Safety and Prevention Act) and high adoption rates. Europe has steady demand with EU needlestick regulation compliance.
Competitive Landscape
Key players include B. Braun, Fresenius, Nipro, JMS, Kawasumi Lab, NxStage Medical, Asahi Kasei, Beldico, Farmasol, Hemoclean, Bain Medical, Tiankang Medical, Hongda Medical, Baihe Medical, Dalian Aohua Medical Polymer Equipment, Sansin Medical, Zhejiang Kindly Medical Devices, and Ningbo Tianyi Medical Appliance.
Market Segmentation
The Safety Arteriovenous Fistula (AVF) Needle market is segmented as below:
By Company
B. Braun
Fresenius
Nipro
JMS
Kawasumi Lab
NxStage Medical
Asahi Kasei
Beldico
Farmasol
Hemoclean
Bain Medical
Tiankang Medical
Hongda Medical
Baihe Medical
Dalian Aohua Medical Polymer Equipment
Sansin Medical
Zhejiang Kindly Medical Devices
Ningbo Tianyi Medical Appliance
Segment by Gauge
15G
16G
17G
18G
Others
Segment by Setting
Hospital
Clinic
Dialysis Center
Exclusive Industry Outlook
Looking ahead, the convergence of safety AVF needle technology with needlestick prevention regulations, chronic kidney disease prevalence, and healthcare worker safety initiatives represents a steady growth opportunity. Development of needles with integrated blood detection for proper vessel placement. Radio-frequency identification (RFID) tracking for inventory management and adverse event reporting. Additionally, the expansion of home hemodialysis will drive demand for user-friendly safety devices. The ability to offer safety arteriovenous fistula needles that combine needlestick prevention, reliable flow rates, and patient comfort—supported by regulatory compliance and clinical training—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ